Abstract
Atherosclerosis (AS) is a condition associated with dysfunctional lipid metabolism and an inflammatory immune microenvironment that remains the leading cause of severe cardiovascular events. Drugs exhibiting both anti-inflammatory and lipid-scavenging activity hold great promise for treating AS. In this study, zeolitic imidazolate framework-8 (ZIF-8) nanoparticles loaded with losartan potassium (LP) were developed as an anti-AS treatment to target both of these therapeutic arms simultaneously. LP@ZIF-8 accumulated within AS target tissues via the enhanced permeability and retention (EPR) effect, as confirmed via in vivo near-infrared fluorescence (NIRF) imaging and wasdisruptedin response tothe low pH. ZIF-8 could activate autophagy, thus regulatinglipid metabolism and restoringcholesterol homeostasis aspreviously reported, while thereleasedLPservedas an anti-inflammatory angiotensin receptor blocker (ARB) inhibitor, which was confirmed via the in vivo treatment studies. As such, our data highlight LP@ZIF-8 as a promising therapeutic agent capable of attenuating the severity of AS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
